Piperidine inhibitors of Janus kinase 3
The present invention relates to new piperidine inhibitors of Janus kinase 3 activity, pharmaceutical compositions thereof, and methods of use thereof.
1. A compound that is
or a pharmaceutically acceptable salt thereof;
wherein each position represented as D has deuterium enrichment of no less than about 10%.
2. The compound of claim 1 , wherein each position represented as D has deuterium enrichment of no less than about 50%.
3. The compound of claim 1 , wherein each position represented as D has deuterium enrichment of no less than about 90%.
4. The compound of claim 1 , wherein each position represented as D has deuterium enrichment of no less than about 98%.
5. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
6. The compound of claim 1 that is
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 6 , wherein each position represented as D has deuterium enrichment of no less than about 50%.
8. The compound of claim 6 , wherein each position represented as D has deuterium enrichment of no less than about 90%.
9. The compound of claim 6 , wherein each position represented as D has deuterium enrichment of no less than about 98%.
10. A pharmaceutical composition comprising a compound of claim 6 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
11. The compound of claim 1 that is
or a pharmaceutically acceptable salt thereof.
12. The compound of claim 11 , wherein each position represented as D has deuterium enrichment of no less than about 50%.
13. The compound of claim 11 , wherein each position represented as D has deuterium enrichment of no less than about 90%.
14. The compound of claim 11 , wherein each position represented as D has deuterium enrichment of no less than about 98%.
15. A pharmaceutical composition comprising a compound of claim 11 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
16. The compound of claim 1 that is
or a pharmaceutically acceptable salt thereof.
17. The compound of claim 16 , wherein each position represented as D has deuterium enrichment of no less than about 50%.
18. The compound of claim 16 , wherein each position represented as D has deuterium enrichment of no less than about 90%.
19. The compound of claim 16 , wherein each position represented as D has deuterium enrichment of no less than about 98%.
20. A pharmaceutical composition comprising a compound of claim 16 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
21. A pharmaceutical composition comprising a compound that is
or a combination thereof;
or a pharmaceutically acceptable salt thereof;
together with a pharmaceutically acceptable carrier;
wherein each position represented as D has deuterium enrichment of no less than about 10%.
22. A method of treating a disorder in a patient wherein the disorder is renal transplant rejection, rheumatoid arthritis, psoriasis, inflammatory bowel disease, dry eye syndrome, asthma, or transplant rejection comprising administering to the patient therapeutically effective amount of a compound of claim 1 .
23. The method of claim 22 , wherein the disorder is renal transplant rejection.
24. The method of claim 22 , wherein the disorder is rheumatoid arthritis.
25. The method of claim 22 , wherein the disorder is psoriasis.
26. The method of claim 22 , wherein the disorder is inflammatory bowel disease.
27. The method of claim 22 , wherein the disorder is dry eye syndrome.
28. The method of claim 22 , wherein the disorder is asthma.
29. The method of claim 22 , wherein the disorder is transplant rejection.